TABLE 1.
Model inputs and 2013 estimates
| Historical | Year | 2013 Estimate | |
|---|---|---|---|
| Anti-HCV+ cases* | 329,760 (209,530–460,280) | 2011 | 322,480 |
| Anti-HCV prevalence* | 0.9 (0.6–1.3) | 0.7% | |
| Total viremic cases* | 253,910 (161,340–354,420) | 2011 | 248,310 |
| Viremic prevalence, % | 0.7 (0.5–1.0) | 0.5 | |
| Proportion viremic, % | 77.0 | 77.0 | |
| Diagnosed, viremic cases | 176,400 | 2013 | 176,400 |
| Proportion of viremic cases diagnosed, % | 70 | 70 | |
| Annual number of newly diagnosed cases, n | 7640 | 2011 | 7640 |
| New infections | 5570 | ||
| New infection rate, per 100,000 | 15.9 | ||
| Treated cases, annually, n (%) | 3600 (1.4) | ||
| HCV risk factors | |||
| Active IDUs with HCV, n | 54,630 | ||
| Proportion of prevalent cases due to active IDU, % | 22 | ||
| Number of previously transfused cases with HCV | 27,310 | ||
| Proportion of prevalent cases due to previous blood transfusion, % | 11 | ||
| HCV genotype, % | |||
| 1a | 36.5 | ||
| 1b | 21.5 | ||
| 1 (other) | 6.1 | ||
| 2 | 14.1 | ||
| 3 | 20.2 | ||
| 4 | 0.3 | ||
| 5 | 0 | ||
| 6 | 0 | ||
| Other | 1.3 |
*
Data presented as % (uncertainty interval). HCV Hepatitis C virus; IDU Injection drug use